These results are highly significant for the development of future therapeutic strategies for HFpEF, as they point towards a personalized approach combining deep diagnostic phenomapping and pharmacological decision making, e.g. personalized MRA therapy.
← all excerpts
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction.
1
—
—